4-Amino-6-methoxypyrimidine

We are 4-Amino-6-methoxypyrimidine CAS:696-45-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Amino-6-methoxypyrimidine
CAS.NO:696-45-7
Synonyms:4-Amino-6-methoxypyrimidine
6-methoxypyrimidin-4-amine
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 290.8±20.0 °C at 760 mmHg
Melting Point 157-160 °C(lit.)
Molecular Formula C5H7N3O
Molecular Weight 125.129
Flash Point 129.7±21.8 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.567
 
Specification:
Appearance:White to yellow to orange powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Sulfamethazine(CAS:57-68-1).

4-Amino-6-methoxypyrimidine


Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.Trimethoxysilane The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.Bis (diisopropilamino) (2-cianoetoxi) fosfina CAS:102691-36-1 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.2-((4-Chlorophenyl)(piperidin-4-yloxy)methyl)pyridine CAS:122368-54-1 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.

Related Products
Product Name
N-BUTYLTRIMETHOXYSILANE View Details
3-UREIDOPROPYLTRIETHOXYSILANE View Details
(R)-(+)-1-Butyn-3-ol View Details
hexamethyldisiloxane manufacturer 2,3,5,6-Tetrafluoro-4-methylbenzyl alcohol manufacturer 3-Amino-2-chloropyridine manufacturer 1-Chloro-3-fluoro-2-(trifluoromethyl)benzene manufacturer 2-(TRIFLUOROMETHYL)PHENYL ISOTHIOCYANATE manufacturer